{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T15:08:38Z","timestamp":1722611318769},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2020,6,19]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This investigation evaluates the pro-apoptotic and anti-inflammatory effects\nof \u03b2-D-mannuronic acid [M2000] compared to diclofenac, based on gene expression involved in\napoptosis and inflammation process [including Bcl2, NF\u03baB, IL-8 and Cd49d] in Peripheral Blood\nMononuclear Cells [PBMCs] of healthy donors under exvivo conditions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Material:<\/jats:title>\n<jats:p>The venous blood samples of twelve healthy volunteers with aged 25-60 years were\ncollected in heparinized tubes. The healthy volunteers were selected from no smoking group and\nwithout using illicit drugs and suffering from diabetes. The PBMCs were separated and divided\ninto untreated and treated groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The PBMCs of each sample were cultured in 5 wells of culture plate, so that the first\nwell consisted of 2\u00d7106 cells exposed by LPS-EB [1\u03bcg\/ml] to stimulate PBMCs and absence of\nM2000 [untreated well]. The second, third, fourth and fifth wells containing 2\u00d7106 cells\/well and\nLPS-EB, after 4 hours incubation at 37\u00baC, received 5, 25 and 50 \u03bcg\/well of M2000 and 5 \u03bcg\/well\nof diclofenac, respectively as treated group.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The PBMCs were separated and RNAs were then extracted and cDNAs synthesized and\ngene expression levels were assessed by qRT-PCR. Furthermore, we studied whether M2000 is\nable to facilitate apoptosis in PBMCs. Our findings represent that the high dose of M2000 could\nsignificantly decrease the expression level of NF\u03baB gene compared to untreated group (p &lt;\n0.0002). On the other hand, no significant change was observed in treated cells with diclofenac. All\ndoses of M2000 could significantly augment apoptosis compared to untreated group [p &lt; 0.0001].\nAdditionally, we observed the same apoptotic effects between the medium dose of M2000 and diclofenac.\nBesides, no significant reduction was shown in expression levels of IL8, Bcl2 and Cd49d\ngenes in all doses of M2000 and diclofenac compared to untreated group. This experiment demonstrates\nM2000 as a new effective NSAID with immunosuppressive characteristics capable of stimulating\napoptosis through lowering expression levels of NF\u03baB gene, which might be probably considered\nas an appropriate drug for reducing the risk of developing inflammatory diseases and cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163815666181109165837","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T11:40:27Z","timestamp":1542022827000},"page":"225-232","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of \u03b2-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules NF\u03baB, IL-8 and Cd49d using Healthy Donor PBMC"],"prefix":"10.2174","volume":"17","author":[{"given":"Atousa","family":"Khalatbari","sequence":"first","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Mahdavi","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahimeh","family":"Jafarnezhad","sequence":"additional","affiliation":[{"name":"Department of Immunology, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaz","family":"Afraei","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzaneh Tofighi","family":"Zavareh","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Aghazadeh","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Ghaderi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Medical oncology Ward, Cancer Research Center. Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Mirshafiey","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-immunol-030409-101311","volume":"28","author":"Rock K.L.","year":"2010","unstructured":"Rock K.L.; Latz E.; Ontiveros F.; Kono H.; The sterile inflammatory response. Annu Rev Immunol 2010,28,321-342","journal-title":"Annu Rev Immunol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"Mantovani A.","year":"2008","unstructured":"Mantovani A.; Allavena P.; Sica A.; Balkwill F.; Cancer-related inflammation. Nature 2008,454(7203),436-444","journal-title":"Nature"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"Grivennikov S.I.","year":"2010","unstructured":"Grivennikov S.I.; Greten F.R.; Karin M.; Immunity, inflammation, and cancer. Cell 2010,140(6),883-899","journal-title":"Cell"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"Johnstone R.W.","year":"2002","unstructured":"Johnstone R.W.; Ruefli A.A.; Lowe S.W.; Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002,108(2),153-164","journal-title":"Cell"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc776","volume":"2","author":"Igney F.H.","year":"2002","unstructured":"Igney F.H.; Krammer P.H.; Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002,2(4),277-288","journal-title":"Nat Rev Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1083\/jcb.124.1.1","volume":"124","author":"Reed J.C.","year":"1994","unstructured":"Reed J.C.; Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994,124(1-2),1-6","journal-title":"J Cell Biol"},{"key":"ref=7","first-page":"1693s","volume":"59","author":"Korsmeyer S.J.","year":"1999","unstructured":"Korsmeyer S.J.; BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999,59(7)(Suppl.),1693s-1700s","journal-title":"Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"Oeckinghaus A.","year":"2009","unstructured":"Oeckinghaus A.; Ghosh S.; The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009,1(4)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1172\/JCI11830","volume":"107","author":"Tak P.P.","year":"2001","unstructured":"Tak P.P.; Firestein G.S.; NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001,107(1),7-11","journal-title":"J Clin Invest"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1357-4310(00)01814-1","volume":"6","author":"Makarov S.S.","year":"2000","unstructured":"Makarov S.S.; NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 2000,6(11),441-448","journal-title":"Mol Med Today"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2006.02.016","volume":"124","author":"Karin M.","year":"2006","unstructured":"Karin M.; Lawrence T.; Nizet V.; Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006,124(4),823-835","journal-title":"Cell"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/jlb.56.5.559","volume":"56","author":"Harada A.","year":"1994","unstructured":"Harada A.; Sekido N.; Akahoshi T.; Wada T.; Mukaida N.; Matsushima K.; Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994,56(5),559-564","journal-title":"J Leukoc Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1126\/science.1281554","volume":"258","author":"Koch A.E.","year":"1992","unstructured":"Koch A.E.; Polverini P.J.; Kunkel S.L.; Harlow L.A.; DiPietro L.A.; Elner V.M.; Elner S.G.; Strieter R.M.; Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992,258(5089),1798-1801","journal-title":"Science"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.4049\/jimmunol.166.5.3484","volume":"166","author":"Ridger V.C.","year":"2001","unstructured":"Ridger V.C.; Wagner B.E.; Wallace W.A.; Hellewell P.G.; Differential effects of CD18, CD29, and CD49 integrin subunit inhibition on neutrophil migration in pulmonary inflammation. J Immunol 2001,166(5),3484-3490","journal-title":"J Immunol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0165-5728(00)00362-3","volume":"111","author":"Muraro P.A.","year":"2000","unstructured":"Muraro P.A.; Leist T.; Bielekova B.; McFarland H.F.; VLA-4\/CD49d downregulated on primed T lymphocytes during interferon-\u03b2 therapy in multiple sclerosis. J Neuroimmunol 2000,111(1-2),186-194","journal-title":"J Neuroimmunol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/9550","volume":"5","author":"Gilroy D.W.","year":"1999","unstructured":"Gilroy D.W.; Colville-Nash P.R.; Willis D.; Chivers J.; Paul-Clark M.J.; Willoughby D.A.; Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999,5(6),698-701","journal-title":"Nat Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.102.035048","volume":"304","author":"Liu B.","year":"2003","unstructured":"Liu B.; Hong J-S.; Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003,304(1),1-7","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","volume":"106","author":"Whelton A.","year":"1999","unstructured":"Whelton A.; Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999,106(5B),13S-24S","journal-title":"Am J Med"},{"key":"ref=19","first-page":"217","volume":"16","author":"Shacter E.","year":"2002","unstructured":"Shacter E.; Weitzman S.A.; Chronic inflammation and cancer. Oncology (Williston Park) 2002,16(2),217-226","journal-title":"Oncology (Williston Park)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00428-005-1264-9","volume":"446","author":"Dolcet X.","year":"2005","unstructured":"Dolcet X.; Llobet D.; Pallares J.; Matias-Guiu X.; NF-kB in development and progression of human cancer. Virchows Arch 2005,446(5),475-482","journal-title":"Virchows Arch"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1357-2725(99)00088-6","volume":"32","author":"Mat\u00e9s J.M.","year":"2000","unstructured":"Mat\u00e9s J.M.; S\u00e1nchez-Jim\u00e9nez F.M.; Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol 2000,32(2),157-170","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev.iy.12.040194.001041","volume":"12","author":"Baeuerle P.A.","year":"1994","unstructured":"Baeuerle P.A.; Henkel T.; Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994,12(1),141-179","journal-title":"Annu Rev Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-065X.2012.01101.x","volume":"246","author":"McCool K.W.","year":"2012","unstructured":"McCool K.W.; Miyamoto S.; DNA damage-dependent NF-\u03baB activation: NEMO turns nuclear signaling inside out. Immunol Rev 2012,246(1),311-326","journal-title":"Immunol Rev"},{"key":"ref=24","author":"Sica A.","year":"2008","unstructured":"Sica A.; Larghi P.; Mancino A.; Rubino L.; Porta C.; Totaro M.G.;  Macrophage polarization in tumour progression Seminars in cancer biology 2008","journal-title":"Macrophage polarization in tumour progression Seminars in cancer biology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jcp.24260","volume":"228","author":"Galdiero M.R.","year":"2013","unstructured":"Galdiero M.R.; Garlanda C.; Jaillon S.; Marone G.; Mantovani A.; Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013,228(7),1404-1412","journal-title":"J Cell Physiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1007\/s11033-014-3329-9","volume":"41","author":"Chen J.","year":"2014","unstructured":"Chen J.; Wang F-L.; Chen W-D.; Modulation of apoptosis-related cell signalling pathways by curcumin as a strategy to inhibit tumor progression. Mol Biol Rep 2014,41(7),4583-4594","journal-title":"Mol Biol Rep"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1164\/ajrccm.160.supplement_1.4","volume":"160","author":"Haslett C.","year":"1999","unstructured":"Haslett C.; Granulocyte apoptosis and its role in the resolution and control of lung inflammation. American journal of respiratory and\n critical care medicine 1999,160(supplement_1),S5-S11","journal-title":"American journal of respiratory and\n critical care medicine"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/sj.onc.1205258","volume":"21","author":"Fulda S.","year":"2002","unstructured":"Fulda S.; Meyer E.; Debatin K-M.; Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002,21(15),2283-2294","journal-title":"Oncogene"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.intimp.2017.11.003","volume":"54","author":"Fattahi M.J.","year":"2018","unstructured":"Fattahi M.J.; Jamshidi A.R.; Mahmoudi M.; Vojdanian M.; Yekaninejad M.S.; Jafarnezhad-Ansariha F.; Ahmadi H.; Rehm B.H.A.; Matsuo H.; Cuzzocrea S.; Hosseini M.; Hashemi S.N.; Aghazadeh Z.; Mirshafiey A.; Evaluation of the efficacy and safety of \u03b2-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I\/II clinical trial. Int Immunopharmacol 2018,54,112-117","journal-title":"Int Immunopharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.intimp.2017.08.018","volume":"52","author":"Roozbehkia M.","year":"2017","unstructured":"Roozbehkia M.; Mahmoudi M.; Aletaha S.; Rezaei N.; Fattahi M.J.; Jafarnezhad-Ansariha F.; Barati A.; Mirshafiey A.; The potent suppressive effect of \u03b2-d-mannuronic acid (M2000) on molecular expression of the TLR\/NF-kB Signaling Pathway in ankylosing spondylitis patients. Int Immunopharmacol 2017,52,191-196","journal-title":"Int Immunopharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10787-017-0386-4","volume":"26","author":"Jafarnezhad-Ansariha F.","year":"2018","unstructured":"Jafarnezhad-Ansariha F.; Yekaninejad M.S.; Jamshidi A.R.; Mansouri R.; Vojdanian M.; Mahmoudi M.; Fattahi M.J.; Hashemi S.N.; Rehm B.H.A.; Matsuo H.; Esposito E.; Cuzzocrea S.; Mirshafiey A.; The effects of \u03b2-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte\/macrophage, J774 cell line. Inflammopharmacology 2018,26(2),375-384","journal-title":"Inflammopharmacology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.pharep.2017.04.015","volume":"69","author":"Mirshafiey A.","year":"2017","unstructured":"Mirshafiey A.; Taeb M.; Mortazavi-Jahromi S.S.; Jafarnezhad-Ansariha F.; Rehm B.H.A.; Esposito E.; Cuzzocrea S.; Matsuo H.; Introduction of \u03b2-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1\/COX-2 activity and gene expression. Pharmacol Rep 2017,69(5),1067-1072","journal-title":"Pharmacol Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10787-018-0475-z","volume":"26","author":"Ahmadi H.","year":"2018","unstructured":"Ahmadi H.; Jamshidi A.R.; Gharibdoost F.; Mahmoudi M.; Rastkari N.; Mostafaei S.; Fattahi M.J.; Vojdanian M.; Cuzzocrea S.; Rehm B.H.A.; Matsuo H.; Hosseini M.; Aghazadeh Z.; Mortazavi-Jahromi S.S.; Mirshafiey A.; A phase I\/II randomized, controlled, clinical trial for assessment of the efficacy and safety of \u03b2-D-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology 2018,26(3),737-745","journal-title":"Inflammopharmacology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10787-017-0410-8","volume":"26","author":"Ahmadi H.","year":"2018","unstructured":"Ahmadi H.; Mahmoudi M.; Gharibdoost F.; Vojdanian M.; Jamshidi A.R.; Fattahi M.J.; Aghazadeh Z.; Barati A.; Mirshafiey A.; Targeting of circulating Th17 cells by \u03b2-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis. Inflammopharmacology 2018,26(1),57-65","journal-title":"Inflammopharmacology"},{"key":"ref=35","first-page":"433","volume":"16","author":"Ahmadi H.","year":"2017","unstructured":"Ahmadi H.; Jamshidi A.R.; Mahmoudi M.; Gharibdoost F.; Vojdanian M.; Fattahi M.J.; Rastkari N.; Aghazadeh Z.; Mirshafiey A.; Hematological improvement of patients with active rheumatoid arthritis by \u03b2-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property. Iran J Allergy Asthma Immunol 2017,16(5),433-442","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2147\/DDDT.S129419","volume":"11","author":"Barati A.","year":"2017","unstructured":"Barati A.; Jamshidi A.R.; Ahmadi H.; Aghazadeh Z.; Mirshafiey A.; Effects of \u03b2-d-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, ROR\u03b3t, IL4 and GATA3 gene expressions in rheumatoid arthritis patients. Drug Des Devel Ther 2017,11,1027-1033","journal-title":"Drug Des Devel Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/08923970701282387","volume":"29","author":"Mirshafiey A.","year":"2007","unstructured":"Mirshafiey A.; Rehm B.; Sotoude M.; Razavi A.; Abhari R.S.; Borzooy Z.; Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis. Immunopharmacol Immunotoxicol 2007,29(1),49-61","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.etap.2007.02.002","volume":"24","author":"Mirshafiey A.","year":"2007","unstructured":"Mirshafiey A.; Rehm B.; Abhari R.S.; Borzooy Z.; Sotoude M.; Razavi A.; Production of M2000 (\u03b2-d-mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol 2007,24(1),60-66","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3109\/08923973.2015.1113296","volume":"37","author":"Fattahi M.J.","year":"2015","unstructured":"Fattahi M.J.; Abdollahi M.; Agha Mohammadi A.; Rastkari N.; Khorasani R.; Ahmadi H.; Tofighi Zavareh F.; Sedaghat R.; Tabrizian N.; Mirshafiey A.; Preclinical assessment of \u03b2-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol 2015,37(6),535-540","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/sji.12519","volume":"85","author":"Aletaha S.","year":"2017","unstructured":"Aletaha S.; Haddad L.; Roozbehkia M.; Bigdeli R.; Asgary V.; Mahmoudi M.; Mirshafiey A.; M2000 (\u03b2-D-Mannuronic Acid) as a Novel antagonist for blocking the TLR2 and TLR4 downstream signalling pathway. Scand J Immunol 2017,85(2),122-129","journal-title":"Scand J Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1515\/jbcpp-2016-0092","volume":"28","author":"Hosseini S.","year":"2017","unstructured":"Hosseini S.; Abdollahi M.; Azizi G.; Fattahi M.J.; Rastkari N.; Zavareh F.T.; Aghazadeh Z.; Mirshafiey A.; Anti-aging effects of M2000 (\u03b2-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model. J Basic Clin Physiol Pharmacol 2017,28(3),249-255","journal-title":"J Basic Clin Physiol Pharmacol"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/167224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T08:26:58Z","timestamp":1598689618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/167224\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6,19]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163815666181109165837","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}